Recognised Life Sciences and high-risk innovation valuation experts.
Known for much more than the number.
Value What Matters!
Let alignment begin.
From the earliest idea to the exit — structuring financial yield across deals, board decisions, and audits.
"We need a number". The number is necessary. It is rarely sufficient.
Those who govern well have seen this pattern. So have the management teams who have been through it once.
What´s needed is clarity — on what matters, on why, and therefore on what it is worth and how to defend it.
When that clarity exists, something shifts.
The investor reads science and management differently, the board elevate to its best and deals get done on terms that hold. Yield has a chance.
This is what we build toward. Not just the number — the position behind it: constructed, reasoned, and built to survive the next question, the next counterpart, the next transaction.
The investor perspective
You may be surprised by the importance we give to the investor perspective.
In field where science and capital must find each other...
More often than not, Eureka! and funding do not come from the same pocket. The potential of an innovation may pass from investor to investor. Financial, then industrial. Or both at once.
...understanding what return requires...
Valuation is one skill. Understanding finance, yield, optionality, from early investors, VC vs. FO nature to capital market operations, it another one. Rarely found together.
...is what makes the science legible to those who fund it
it is all about intersecting what makes the mandate of each party readable to the others. Reading imperatives simultaneously.
"From financing to deal making.
From decision making to accounting.
Generating and maximizing options.
It is a strategic framework."
Think about what you need most
To articulate value over the long game.
Number that holds
Fair value, independent opinion, accounting valuation.
IFRS. US GAAP. HGB. Transfer Price. IP Value.
When the standard must be applied with precision and the reasoning must survive audit.
→ Fair Value
Decision that holds
Value for Decision Makers.
When the asset is strong and the financial narrative is not yet.
When the room needs to reach a conclusion and the parties don't yet speak the same language.
New to this
Incubators - First timers
When you sense there is more to learn
When a 1:1 crossing silos from science to finance, through deal making and legal realities — would change what you build.
Deal value that holds
High stake - Very contingent
When control will partially escape you and the terms need to carefully be thought through.
When this move closes others.
We see.
You lead.
Every year we meticulously focus on
3-6bn Asset value
100 R&Dprojects
Twenty years of mandates at the intersection of science, capital, and governance — in the rooms where those worlds must find each other, and rarely do without help.